Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02799381 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)
A Phase 3 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 63
- Enrollment target
NCT02799381 is a Phase 3 study that has completed, run by AbbVie. The registered enrollment target is 63 participants.
The verdict
NCT02799381, a Phase 3 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 63 participants
- Enrollment target
Study Summary
The primary objective of this study was to examine the effect of levodopa-carbidopa intestinal gel (LCIG) compared with optimized medical treatment (OMT) on dyskinesia in participants with advanced Parkinson's disease (PD).
Interventions
- DRUG Levodopa-Carbidopa Intestinal Gel (LCIG)
- DRUG Optimized antiparkinsonian treatment
- DEVICE CADD-Legacy ambulatory infusion pump
- DEVICE Percutaneous endoscopic gastrostomy tube
- DEVICE Jejunal extension tube
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2017-02-09 |
| Est. Completion | 2019-09-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02799381
The ClinicalTrials.gov registry entry for NCT02799381 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Levodopa-Carbidopa Intestinal Gel (LCIG) is the first listed.
NCT02799381 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02799381 about?
NCT02799381 is a clinical study titled "A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)". The primary objective of this study was to examine the effect of levodopa-carbidopa intestinal gel (LCIG) compared with optimized medical treatment (OMT) on dyskinesia in participants with advanced Parkinson's disease (PD).
What is the current status of trial NCT02799381?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 63 participants. The study started on 2017-02-09. Estimated completion is 2019-09-19.
What interventions are being tested in trial NCT02799381?
The interventions under investigation include: Levodopa-Carbidopa Intestinal Gel (LCIG) (DRUG), Optimized antiparkinsonian treatment (DRUG), CADD-Legacy ambulatory infusion pump (DEVICE), Percutaneous endoscopic gastrostomy tube (DEVICE), Jejunal extension tube (DEVICE).
Who is sponsoring clinical trial NCT02799381?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.